Skip to main content
. 2015 Mar 26;19(1):43–47. doi: 10.5114/wo.2015.50012

Table 2.

Patients’ characteristics (n = 18) at qualifications to 90Y-IT

Group characteristics Frequency
Bone marrow involvement 3 (17%)
Lymph nodes enlargement > 2 cm 6 (33%)
2–4 prior chemotherapy regimens 6 (33%)
Previous treatment with rituximab 12 (67%)